Sanofi buys Synthorx for $2.5bn
Acquisition at triple market value accelerates French drug maker's push into cancer drugs under new CEO
09 December 2019 - 16:35
London — French pharmaceutical firm Sanofi agreed to buy US biotech company Synthorx for $2.5bn, almost triple its market value, accelerating a push into cancer under new CEO Paul Hudson.
Sanofi will pay $68 a share in cash for Synthorx, the companies said on Monday. Shares of the unprofitable San Diego-based company closed at $25.03 on Friday, having surged 40% last week...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.